Pappas Capital LLC
06/13/2011 | Press release | Archived content
Milestone completes $13 million round of equity financing
News | 06. 13. 2011
Milestone Pharmaceuticals
June 13, 2011
Milestone Pharmaceuticals Inc., a cardiovascular drug development company, announces the completion of a $13 million round of equity financing. The round is led by Pappas Ventures, the Business Development Bank of Canada (BDC), and GO Capital. Other participating investors are Fonds de solidarité FTQ (FSTQ), and the company's previous investors, iNovia Healthcare Ventures, who played a key role during the Company's founding and was the lead investor in the earlier rounds, and Fonds Bio-Innovation.
Funding will be used to continue development of MSP-2017 and related products, the company's lead candidate series for episodic treatment of transient cardiovascular conditions such as paroxysmal supraventricular tachycardia (PSVT), and stable angina, amongst others.
Pappas Capital LLC published this content on June 13, 2011, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:07 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]